Clinical Trials Directory

We are doing this study to find the most effective, safe dose of an experimental drug called quizartinib (the study drug) for people with acute myeloid leukemia (AML) who do not have a FLT3-ITD mutation and who have not completed any treatment for their disease.

We are doing this study to find the most effective, safe dose of an experimental drug called linvoseltamab (the study drug) in people with newly diagnosed multiple myeloma.

We are doing this study to find out how safe and effective it is to give people with recurrent glioblastoma two infusions of an experimental drug called lerapolturev (the study drug) in residual disease (within tumor margins) after surgery. After these two doses, we will give further doses of the study drug as injections in the subcutaneous area (under the skin) around the lymph nodes of the head and neck. We also want to know how well the study drug works compared to lomustine, which is a standard form of chemotherapy (drug used to kill cancer cells).

We are doing this study to find out if a personalized exercise program designed for lung cancer patients can help with recovery from lung surgery. The study's exercise program is delivered over the phone.

We created this registry for people with rare breast tumors to help us learn more about them and how to better treat people in the future.

We are doing this study to find out if an experimental drug called ravulizumab (the study drug) is a safe and effective option to prevent or reduce the severity of delayed graft function after people with end-stage kidney disease (ESKD) get a kidney transplant.

This study lasts for about one and a half months. People will go to the doctor up to six times in person and have one phone call visit. The first visit will take about four and a half hours and will include a brain scan and tests to see how well someone can do certain tasks. This long visit can be split into two shorter visits if that is easier. After that, there will be three visits where people get a special kind of treatment, and each of those visits will take about an hour and a half.

We are doing this study to find out if the experimental combination of the drugs finalimab and cemiplimab (the study drugs) is a safe and effective option for people with high-risk melanoma. We want to see how well the study drugs work compared to treatment with pembrolizumab.